Select Your Location:
Global
France
Italy

NMA: Comparison of efficacy between BTKis in high-risk R/R CLL

Disease State: Hematologic malignancies

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Network Meta-Analysis (NMA) methodology.

Video
26 May 2025

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Matching Adjusted Indirect Comparison (MAIC) methodology.

Video
26 May 2025

BGB-3111-215 (NCT04116437) is a Phase 2 study evaluating the safety of zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

Reading
23 May 2025